{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:27:06Z","timestamp":1793914026399,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e01075","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:33:44Z","timestamp":1789724024000},"page":"e01075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab"],"prefix":"10.1016","volume":"23","author":[{"given":"Lars","family":"Masanneck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Trautmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"von Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Hagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Vach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Voth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schuette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Benkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Deffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e01075_bib1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e01075_bib2","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing\u2013remitting multiple sclerosis","volume":"27","author":"Trojano","year":"2021","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2026.e01075_bib3","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200321","article-title":"Pharmacokinetics and pharmacodynamics of natalizumab 6-Week dosing vs continued 4-Week dosing for relapsing-remitting multiple sclerosis","volume":"11","author":"Foley","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e01075_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s13760-024-02480-6","article-title":"Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis","volume":"124","author":"Rabea","year":"2024","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.neurot.2026.e01075_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2026.e01075_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117622","article-title":"Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic","volume":"429","author":"Bringeland","year":"2021","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurot.2026.e01075_bib7","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e01075_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102020","article-title":"End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?","volume":"41","author":"Cath\u00e9rine","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e01075_bib9","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000706","article-title":"Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker","volume":"7","author":"Foley","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e01075_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000678","article-title":"Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy","volume":"7","author":"Bringeland","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e01075_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116880","article-title":"Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: a prospective 1-year follow-up study","volume":"415","author":"Bringeland","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurot.2026.e01075_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106146","article-title":"Improvement of fatigue, depression, and processing speed two weeks post natalizumab infusion in multiple sclerosis: no difference between standard and extended interval dosing schedules","volume":"92","author":"Leodori","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e01075_bib13","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1177\/13524585241293940","article-title":"Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients","volume":"30","author":"Toorop","year":"2024","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2026.e01075_bib14","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000271","article-title":"Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e01075_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313153","article-title":"Effect of natalizumab on sNfL and sGFAP levels in multiple sclerosis patients","volume":"25","author":"Sainz-Amo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2026.e01075_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/jon.12082","article-title":"Identifying the start of multiple sclerosis injury: a serial DTI study","volume":"24","author":"Ontaneda","year":"2014","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.neurot.2026.e01075_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3174\/ajnr.A4946","article-title":"Measuring brain tissue integrity during 4 years using diffusion tensor imaging","volume":"38","author":"Ontaneda","year":"2017","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.neurot.2026.e01075_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00115-023-01581-6","article-title":"[digital medicine in neurological research-between hype and evidence]","volume":"95","author":"Masanneck","year":"2024","journal-title":"Nervenarzt"},{"key":"10.1016\/j.neurot.2026.e01075_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41746-023-00767-1","article-title":"Evidence from clinicalTrials.gov on the growth of digital health technologies in neurology trials","volume":"6","author":"Masanneck","year":"2023","journal-title":"npj Digit Med"},{"key":"10.1016\/j.neurot.2026.e01075_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.70137","article-title":"Digital activity markers in chronic inflammatory demyelinating polyneuropathy","author":"Masanneck","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2026.e01075_bib21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00415-016-8334-6","article-title":"Continuous daily assessment of multiple sclerosis disability using remote step count monitoring","volume":"264","author":"Block","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2026.e01075_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41746-024-01025-8","article-title":"Modeling multiple sclerosis using Mobile and wearable sensor data","volume":"7","author":"Gashi","year":"2024","journal-title":"npj Digit Med"},{"key":"10.1016\/j.neurot.2026.e01075_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e01075_bib24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/135245859900500409","article-title":"The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment","volume":"5","author":"Fischer","year":"1999","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurot.2026.e01075_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2019.116137","article-title":"MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation","volume":"202","author":"Tournier","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurot.2026.e01075_bib26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neuroimage.2016.08.016","article-title":"Denoising of diffusion MRI using random matrix theory","volume":"142","author":"Veraart","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurot.2026.e01075_bib27","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/mrm.26054","article-title":"Gibbs-ringing artifact removal based on local subvoxel-shifts","volume":"76","author":"Kellner","year":"2016","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.neurot.2026.e01075_bib28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.neuroimage.2015.10.019","article-title":"An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging","volume":"125","author":"Andersson","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurot.2026.e01075_bib29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S1053-8119(03)00336-7","article-title":"How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging","volume":"20","author":"Andersson","year":"2003","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurot.2026.e01075_bib30","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.neuroimage.2006.02.024","article-title":"Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data","volume":"31","author":"Smith","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurot.2026.e01075_bib31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e01075_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.27096","article-title":"Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under b-cell depleting treatment in multiple sclerosis","volume":"97","author":"Benkert","year":"2025","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e01075_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120447","article-title":"Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay","volume":"577","author":"Booth","year":"2025","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.neurot.2026.e01075_bib34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/acn3.70207","article-title":"Annual 12-Week dosing gap of natalizumab: clinical efficacy, blood biomarkers, and CSF cell composition","volume":"13","author":"Berkovich","year":"2026","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2026.e01075_bib35","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2018.14854","article-title":"The physical activity guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.neurot.2026.e01075_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jshs.2023.10.010","article-title":"2024 adult compendium of physical activities: a third update of the energy costs of human activities","volume":"13","author":"Herrmann","year":"2024","journal-title":"J Sport Health Sci"},{"key":"10.1016\/j.neurot.2026.e01075_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2024-335673","article-title":"Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis","author":"Winter","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2026.e01075_bib38","article-title":"Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy","volume":"5","author":"Deffner","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.neurot.2026.e01075_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mri.2023.09.010","article-title":"A systematic review of microstructural abnormalities in multiple sclerosis detected with NODDI and DTI models of diffusion-weighted magnetic resonance imaging","volume":"104","author":"Caranova","year":"2023","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.neurot.2026.e01075_bib40","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3174\/ajnr.A4690","article-title":"White matter diffusion changes during the first year of natalizumab treatment in relapsing-remitting multiple sclerosis","volume":"37","author":"Wiebenga","year":"2016","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.neurot.2026.e01075_bib41","article-title":"Microstructure abnormalities of diffusion tensor imaging measures in first-episode, treatment-na\u00efve adolescents with major depressive disorder: an integrated AFQ and TBSS study","volume":"15","author":"Zhang","year":"2025","journal-title":"Brain Behav"},{"key":"10.1016\/j.neurot.2026.e01075_bib42","article-title":"No evidence of fluctuations in daily step count between infusions in people with multiple sclerosis treated with anti-CD20 monoclonal antibodies","volume":"11","author":"Block","year":"2025","journal-title":"Mult Scler J \u2013 Exp Transl Clin"},{"key":"10.1016\/j.neurot.2026.e01075_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105104","article-title":"Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity","volume":"80","author":"Woelfle","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e01075_bib44","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/ehjdh\/ztae055","article-title":"Long-term adherence to a wearable for continuous behavioural activity measuring in the SafeHeart implantable cardioverter defibrillator population","volume":"5","author":"Frodi","year":"2024","journal-title":"Eur Heart J - Digit Health"},{"key":"10.1016\/j.neurot.2026.e01075_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.27008","article-title":"Assessment of hypertension control among adults participating in a Mobile technology blood pressure self-Management program","volume":"4","author":"Gazit","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792600245X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792600245X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:16:28Z","timestamp":1793913388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792600245X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S187874792600245X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01075","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01075"}}